Молимо вас користите овај идентификатор за цитирање или овај линк до ове ставке:
https://open.uns.ac.rs/handle/123456789/14200
Назив: | Balancing benefits and risks in the era of biologics | Аутори: | Adami G. Saag K. Chapurlat R. Guañabens N. Haugeberg G. Lems W. Matijević, Radmila Peel N. Poddubnyy D. Geusens P. |
Датум издавања: | 1-јан-2019 | Часопис: | Therapeutic Advances in Musculoskeletal Disease | Сажетак: | © The Author(s), 2019. Biologics are substances synthetized from biological sources used in the prevention and treatment of several diseases. Rheumatologists have many years of experience with biologics for the treatment of immune-mediated diseases and osteoporosis. Randomized clinical trials and postmarketing studies have demonstrated that treatment with biologics can result, albeit infrequently, in serious adverse events. To date, several risk mitigation strategies have been identified and implemented. The objective of the present perspective review is to examine the risk mitigation strategies of biologic treatments, with special focus on anti-tumor necrosis factors and denosumab. | URI: | https://open.uns.ac.rs/handle/123456789/14200 | ISSN: | 1759720X | DOI: | 10.1177/1759720X19883973 |
Налази се у колекцијама: | MDF Publikacije/Publications |
Приказати целокупан запис ставки
SCOPUSTM
Навођења
7
проверено 20.11.2023.
Преглед/и станица
28
Протекла недеља
7
7
Протекли месец
0
0
проверено 10.05.2024.
Google ScholarTM
Проверите
Алт метрика
Ставке на DSpace-у су заштићене ауторским правима, са свим правима задржаним, осим ако није другачије назначено.